BioSpace News Archive

Castlight Health, Inc. (NYSE: CSLT) today announced that on September 1 st , 2020, Castlight was notified by the New York Stock Exchange (“NYSE”) that it has regained compliance with the NYSE’s continued listing standards.

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in three upcoming virtual investor conferences. Wells Fargo’s 2020 Healthcare Conference is scheduled for September 9-10, 2020. Zymeworks is presenting on Wednesday, September 9, 2020 at 11:20 a.m. ET. Citi’s 15 th Annual BioPharma

Ocular Therapeutix, Inc. a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that it will present and host investor meetings at the following conferences:.

AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that members of its senior management team are scheduled to participate in three upcoming virtual investor conferences.

BELLUS Health Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will participate in two upcoming virtual healthcare investor conferences.

Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in three upcoming virtual conferences in September:

Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced the appointment of Robert Ross , M.D., to its Board of Directors. Dr. Ross currently s

NeuroPointDX, a division of Stemina Biomarker Discovery, today announced the appointment of two new board members with extensive experience in the development and commercialization of new molecular diagnostic tests. Barbara Handelin, PhD was founding Director of the DNA Diagnostics Lab at Integrated Genetics (acquired by LabCorp @ $925M), and Tony Shuber was Chief Technology Officer and cofounder of Exact Science Corporati

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D., will participate in an ophthalmology panel discussion during Citi’s 15th Annual BioPharma Virtual Conference, taking place September 8-11, 2020. In addition, Aldeyra’s senior management will host one-on-one

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (“Regulus”), today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will present at the Wells Fargo Virtual Healthcare Conference on Wednesd